In yesterday’s Wall Street session, Navidea Biopharmaceuticals Inc. (AMEX:NAVB) shares traded at $0.12, up 3.45% from the previous session.
1 analysts cover Navidea Biopharmaceuticals Inc. (AMEX:NAVB), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $8.00, we find $8.00. Given the previous closing price of $0.12, this indicates a potential upside of 6566.67 percent. NAVB stock price is now 31.34% away from the 50-day moving average and -38.51% away from the 200-day moving average. The market capitalization of the company currently stands at $12.00M.
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $8.00 as their price target over the next twelve months.
With the price target reduced from $3 to $2, Aegis Capital maintained Hold rating for Navidea Biopharmaceuticals Inc. (AMEX: NAVB).
A total of 26.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NAVB stock. A new stake in Navidea Biopharmaceuticals Inc. shares was purchased by SUSQUEHANNA INTERNATIONAL GROUP, LLP during the first quarter worth $15,000. BOOTHBAY FUND MANAGEMENT, LLC invested $5,000 in shares of NAVB during the first quarter. In the first quarter, CUBIST SYSTEMATIC STRATEGIES, LLC acquired a new stake in Navidea Biopharmaceuticals Inc. valued at approximately $1,000.
During the past 12 months, Navidea Biopharmaceuticals Inc. has had a low of $0.06 and a high of $0.35. The fifty day moving average price for NAVB is $0.0922 and a two-hundred day moving average price translates $0.1951 for the stock.
The latest earnings results from Navidea Biopharmaceuticals Inc. (AMEX: NAVB) was released for Jun, 2023.
Navidea Biopharmaceuticals Inc.(NAVB) Company Profile
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi’s sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
